 
| IPAD-DB ID | D01183 | 
| Name | Adenosine Triphosphate | 
| Category | Drugs | 
| 2D Structure |  | 
| 3D Structure | |
| Molecular Formula | C 1 0 H 1 6 N 5 O 1 3 P 3 | 
| Molecular Weight | 507.18 | 
| IUPAC Name | [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate | 
| InChI | InChI=1S/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1 | 
| InChIKey | ZKHQWZAMYRWXGA-KQYNXXCUSA-N | 
| Canonical SMILES | C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N | 
| PubChem CID | 5957 | 
| DrugBank Accession Number | - | 
| CAS Registry Number | - | 
| Ki | - | 
| EC50 | - | 
| IC50 | - | 
| Inhibition | - | 
| Toxicity | - | 
| ROS(reactive oxygen species) | - | 
| Metal Chelating | - | 
| BBB(blood-brain barrier) | - | 
| Target Protein | Aβ | 
| Effects | - | 
| Research Models | - | 
| Ref. Link | 
| Molecular Weight(Computed by SwissADME) | 507.18 | 
| Hac(Computed by SwissADME) | 31 | 
| Volume(Computed by ADMETlab 2.0) | 374.04 | 
| Density(Computed by ADMETlab 2.0) | 1.355 | 
| nRing(Computed by ADMETlab 2.0) | 3 | 
| MaxRing(Computed by ADMETlab 2.0) | 9 | 
| nHet(Computed by ADMETlab 2.0) | 21 | 
| fChar(Computed by ADMETlab 2.0) | 0 | 
| nRig(Computed by ADMETlab 2.0) | 22 | 
| Flexibility(Computed by ADMETlab 2.0) | 0.364 | 
| Stero Centers(Computed by ADMETlab 2.0) | 4 | 
| LogS(Computed by ADMETlab 2.0) | -0.543 | 
| LogD(Computed by ADMETlab 2.0) | -1.539 | 
| logP(Computed by ADMETlab 2.0) | -3.918 | 
| TPSA(Computed by SwissADME) | 308.56 | 
| Hbond Acceptor(Computed by SwissADME) | 16 | 
| Hbond Donor(Computed by SwissADME) | 7 | 
| Rotatable Bonds(Computed by SwissADME) | 8 | 
| GI Absorption(Computed by SwissADME) | Low | 
| BBB(blood-brain barrier) Permeant(Computed by SwissADME) | No | 
| P-gp Substrate(Computed by SwissADME) | Yes | 
| CYP1A2 Inhibitor(Computed by SwissADME) | No | 
| CYP2C19 Inhibitor(Computed by SwissADME) | No | 
| CYP2C9 Inhibitor(Computed by SwissADME) | No | 
| CYP2D6 Inhibitor(Computed by SwissADME) | No | 
| CYP3A4 Inhibitor(Computed by SwissADME) | No | 
| log Kp(Skin Permeation)(Computed by SwissADME) | -13.45 | 
| Lipinski(Computed by SwissADME) | 3 | 
| Ghose(Computed by SwissADME) | 2 | 
| Veber(Computed by SwissADME) | 1 | 
| Egan(Computed by SwissADME) | 1 | 
| Muegge(Computed by SwissADME) | 4 | 
| Bioavailability Score(Computed by SwissADME) | 0.11 |